In collaboration with the Gorlin Syndrome Alliance, Medicus is pursuing an Expanded Access IND program to provide Gorlin Syndrome patients with multiple or inoperable BCCs access to SkinJect™, the ...
Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics ...
The MarketWatch News Department was not involved in the creation of this content. WINDHAM, N.H., April 9, 2026 /PRNewswire/ -- Cardiovascular demand continues to rise across the United States, placing ...
WINDHAM, N.H., April 9, 2026 /PRNewswire/ -- Cardiovascular demand continues to rise across the United States, placing increasing pressure on healthcare organizations to maintain access to cardiology ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
SkinJect™, a novel localized immuno-oncology precision product focused on non-melanoma skin diseases, especially basal cell carcinoma (BCC) and Gorlin Syndrome, a rare autosomal dominant disease also ...
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...
NEW YORK CITY, NY / ACCESS Newswire / April 7, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX), a precision-guided biotech and life sciences company advancing innovative therapeutic platforms, has entered ...
Barber Motorsports Park (Leeds, Ala.) — George Barber Jr. took over the family dairy business and expanded into ice cream stores and then properties such as warehouses and office buildings. And boy ...
The eye is essentially a biological camera. It uses the light around us to create spectacular images that help us navigate the world as visual creatures. Like many modern cameras, the eye focuses ...
The clarification addresses how topline data released in March should be interpreted, particularly regarding a device-only study arm that does not contain active drug, according to the company.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results